Brief: Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial
18/11/2024 13:13
Nov 18 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2
STENOPARIB
TRIAL AND STRATEGIC CORPORATE ADVANCEMENTS
* ALLARITY THERAPEUTICS INC - MAINTAINS CASH BALANCE OF
$18.5
MILLION
* ALLARITY THERAPEUTICS INC - TWO PATIENTS EXCEED 14 MONTHS
ON
TREATMENT IN PHASE 2 TRIAL
Source text: ID:nGNXVGJSz
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic